TD Cowen Reiterates Buy Rating on Regeneron Pharma (REGN): "if results are replicated in US, could lead to preferential prescribing"
Tweet Send to a Friend
TD Cowen analyst Tyler Van Buren reiterated a Buy rating and $880.00 price target on Regeneron Pharma (NASDAQ: REGN)The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
